NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients
Top Cited Papers
- 13 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 143 (5), 1414-1430
- https://doi.org/10.1093/brain/awaa084
Abstract
Primary progressive multiple sclerosis is a poorly understood disease entity with no specific prognostic biomarkers and scarce therapeutic options. We aimed to identify disease activity biomarkers in multiple sclerosis by performing an RNA sequencing approach in peripheral blood mononuclear cells from a discovery cohort of 44 untreated patients with multiple sclerosis belonging to different clinical forms and activity phases of the disease, and 12 healthy control subjects. A validation cohort of 58 patients with multiple sclerosis and 26 healthy control subjects was included in the study to replicate the RNA sequencing findings. The RNA sequencing revealed an interleukin 1 beta (IL1B) signature in patients with primary progressive multiple sclerosis. Subsequent immunophenotyping pointed to blood monocytes as responsible for the IL1B signature observed in this group of patients. Functional experiments at baseline measuring apoptosis-associated speck-like protein containing a CARD (ASC) speck formation showed that the NOD-leucine rich repeat and pyrin containing protein 3 (NLRP3) inflammasome was overactive in monocytes from patients with primary progressive multiple sclerosis, and canonical NLRP3 inflammasome activation with a combination of ATP plus lipopolysaccharide was associated with increased IL1B production in this group of patients. Primary progressive multiple sclerosis patients with high IL1B gene expression levels in peripheral blood mononuclear cells progressed significantly faster compared to patients with low IL1B levels based on the time to reach an EDSS of 6.0 and the Multiple Sclerosis Severity Score. In agreement with peripheral blood findings, both NLRP3 and IL1B expression in brain tissue from patients with primary progressive multiple sclerosis was mainly restricted to cells of myeloid lineage. Treatment of mice with a specific NLRP3 inflammasome inhibitor attenuated established experimental autoimmune encephalomyelitis disease severity and improved CNS histopathology. NLRP3 inflammasome-specific inhibition was also effective in reducing axonal damage in a model of lipopolysaccharide-neuroinflammation using organotypic cerebellar cultures. Altogether, these results point to a role of IL1B and the NLRP3 inflammasome as prognostic biomarker and potential therapeutic target, respectively, in patients with primary progressive multiple sclerosis.Funding Information
- Fondo de Investigación Sanitaria (PI16/00924)
- Ministry of Science and Innovation
- Ministry of the Economy and Competitiveness (PI15/00963, PI18/00357, MTM2015-64465-C2-1-R)
- Ministerio de Economía, Industria y Competitividad – Fondo Europeo de Desarrollo Regional (SAF2017-88276-R)
- European Research Council (ERC-2013-CoG 614578)
- Generalitat de Catalunya Suport Grups de Recerca (SGR 622)
- Red Española de Esclerosis Múltiple (RD16/0015/0019)
- Fondo de Investigación Sanitaria
- Europa”; and ARSEP Foundation
This publication has 39 references indexed in Scilit:
- Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)Brain Pathology, 2017
- A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseasesNature Medicine, 2015
- Body fluid biomarkers in multiple sclerosisThe Lancet Neurology, 2014
- Oxidative Stress and Proinflammatory Cytokines Contribute to Demyelination and Axonal Damage in a Cerebellar Culture Model of NeuroinflammationPLOS ONE, 2013
- Predictors of long‐term outcome in multiple sclerosis patients treated with interferon betaAnnals of Neurology, 2013
- Activated Human CD4+CD45RO+ Memory T-Cells Indirectly Inhibit NLRP3 Inflammasome Activation through Downregulation of P2X7R SignallingPLOS ONE, 2012
- Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitisJournal of Neuroimmunology, 2012
- MRI as a marker for disease heterogeneity in multiple sclerosisNeurology, 2005
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- The natural history of multiple sclerosis:a geographically based studyBrain, 1999